Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending oral dose study of GSK2239633 in healthy male volunteers
NL-OMON36158Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in asthma and allergic bronchopulmonary aspergillosis (ABPA) comparing GSK2239633 with Placebo (2 arms). Primary endpoints: Adverse events and Clinically relevant changes in safety parameters. Started Apr 2011; status: active, not recruiting.
02
Drugs
GSK2239633
03
Conditions
asthmaallergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NL-OMON36158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36158.